Literature DB >> 28784669

Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.

Maria F Mojica1,2, Krisztina M Papp-Wallace1,2,3, Magdalena A Taracila2,3, Melissa D Barnes2,3, Joseph D Rutter2, Michael R Jacobs4,5, John J LiPuma6, Thomas J Walsh7, Alejandro J Vila8,9, Robert A Bonomo10,3,11,12,13.   

Abstract

Stenotrophomonas maltophilia is an emerging opportunistic pathogen, classified by the World Health Organization as one of the leading multidrug-resistant organisms in hospital settings. The need to discover novel compounds and/or combination therapies for S. maltophilia is urgent. We demonstrate the in vitro efficacy of aztreonam-avibactam (ATM-AVI) against S. maltophilia and kinetically characterize the inhibition of the L2 β-lactamase by avibactam. ATM-AVI overcomes aztreonam resistance in selected clinical strains of S. maltophilia, addressing an unmet medical need.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  S. maltophilia; avibactam; aztreonam

Mesh：

Substances：

Year:  2017        PMID： 28784669      PMCID： PMC5610502          DOI： 10.1128/AAC.00777-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.

Authors:  Douglas J Biedenbach; Krystyna Kazmierczak; Samuel K Bouchillon; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

2.  Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease.

Authors:  Valerie Waters; Yvonne Yau; Sudha Prasad; Annie Lu; Eshetu Atenafu; Ian Crandall; Stephanie Tom; Elizabeth Tullis; Felix Ratjen
Journal:  Am J Respir Crit Care Med       Date:  2010-10-01       Impact factor: 21.405

Review 3.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

Review 4.  Antibiotic-resistant gram-negative bacterial infections in patients with cancer.

Authors:  Federico Perez; Javier Adachi; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2014-11-15       Impact factor: 9.079

5.  The role of AmpR in regulation of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.

Authors:  Cheng-Wen Lin; Yi-Wei Huang; Rouh-Mei Hu; Kai-Hung Chiang; Tsuey-Ching Yang
Journal:  Res Microbiol       Date:  2008-11-28       Impact factor: 3.992

6.  The β-lactamase gene regulator AmpR is a tetramer that recognizes and binds the D-Ala-D-Ala motif of its repressor UDP-N-acetylmuramic acid (MurNAc)-pentapeptide.

Authors:  Grishma Vadlamani; Misty D Thomas; Trushar R Patel; Lynda J Donald; Thomas M Reeve; Jörg Stetefeld; Kenneth G Standing; David J Vocadlo; Brian L Mark
Journal:  J Biol Chem       Date:  2014-12-05       Impact factor: 5.157

7.  Stenotrophomonas maltophilia Phenotypic and Genotypic Diversity during a 10-year Colonization in the Lungs of a Cystic Fibrosis Patient.

Authors:  Arianna Pompilio; Valentina Crocetta; Dipankar Ghosh; Malabika Chakrabarti; Giovanni Gherardi; Luca Agostino Vitali; Ersilia Fiscarelli; Giovanni Di Bonaventura
Journal:  Front Microbiol       Date:  2016-09-30       Impact factor: 5.640

8.  Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureus.

Authors:  Sibylle Junge; Dennis Görlich; Martijn den Reijer; Bärbel Wiedemann; Burkhard Tümmler; Helmut Ellemunter; Angelika Dübbers; Peter Küster; Manfred Ballmann; Cordula Koerner-Rettberg; Jörg Große-Onnebrink; Eberhardt Heuer; Wolfgang Sextro; Jochen G Mainz; Jutta Hammermann; Joachim Riethmüller; Ute Graepler-Mainka; Doris Staab; Bettina Wollschläger; Rüdiger Szczepanski; Antje Schuster; Friedrich-Karl Tegtmeyer; Sivagurunathan Sutharsan; Alexandra Wald; Jerzy-Roch Nofer; Willem van Wamel; Karsten Becker; Georg Peters; Barbara C Kahl
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

9.  The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants.

Authors:  Lisa C Crossman; Virginia C Gould; J Maxwell Dow; Georgios S Vernikos; Aki Okazaki; Mohammed Sebaihia; David Saunders; Claire Arrowsmith; Tim Carver; Nicholas Peters; Ellen Adlem; Arnaud Kerhornou; Angela Lord; Lee Murphy; Katharine Seeger; Robert Squares; Simon Rutter; Michael A Quail; Mari-Adele Rajandream; David Harris; Carol Churcher; Stephen D Bentley; Julian Parkhill; Nicholas R Thomson; Matthew B Avison
Journal:  Genome Biol       Date:  2008-04-17       Impact factor: 13.583

Review 10.  Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.

Authors:  Ya-Ting Chang; Chun-Yu Lin; Yen-Hsu Chen; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2015-09-02       Impact factor: 5.640
View more
  19 in total

Review 1.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

2.  Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.

Authors:  Cécile Emeraud; Lelia Escaut; Athénaïs Boucly; Nicolas Fortineau; Rémy A Bonnin; Thierry Naas; Laurent Dortet
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  Aztreonam Combination Therapy: An Answer to Metallo-β-Lactamase-Producing Gram-Negative Bacteria?

Authors:  Ryan K Shields; Yohei Doi
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

4.  [New antibiotics for severe infections due to multidrug-resistant pathogens : Definitive treatment and escalation].

Authors:  D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

Review 5.  Epidemiology of β-Lactamase-Producing Pathogens.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

6.  Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.

Authors:  Helio S Sader; Leonard R Duncan; S J Ryan Arends; Cecilia G Carvalhaes; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

7.  ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases.

Authors:  Michael R Jacobs; Ayman M Abdelhamed; Caryn E Good; Daniel D Rhoads; Kristine M Hujer; Andrea M Hujer; T Nicholas Domitrovic; Susan D Rudin; Sandra S Richter; David van Duin; Barry N Kreiswirth; Chris Greco; Derrick E Fouts; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 8.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

9.  Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.

Authors:  M Biagi; D Lamm; K Meyer; A Vialichka; M Jurkovic; S Patel; R E Mendes; Z P Bulman; E Wenzler
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

10.  Stenotrophomonas maltophilia Susceptibility Testing Challenges and Strategies.

Authors:  Daniel D Rhoads
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.